Cyclophosphamide Injection, Solution, Concentrate
NDC 0781-3530
Product Information
Cyclophosphamide is a NDA-approved product labeled by Sandoz Inc. Cyclophosphamide is used to treat various types of cancer. It is supplied as a injection, solution, concentrate for intravenous administration. This product entry covers the primary NDC 0781-3530 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 0781-3530?
What are the uses of this product?
What are Active Ingredients of this product?
- CYCLOPHOSPHAMIDE 2000 mg/20mL - Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CYCLOPHOSPHAMIDE (UNII: 8N3DW7272P)
- 4-HYDROXYCYCLOPHOSPHAMIDE (UNII: 1XBF4E50HS) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- ALCOHOL (UNII: 3K9958V90M)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2679073 - cycloPHOSphamide 100 MG/ML Injectable Solution
- RxCUI: 2679073 - cyclophosphamide 100 MG/ML Injectable Solution
- RxCUI: 2679073 - cyclophosphamide (as cyclophosphamide monohydrate) 100 MG/ML Injectable Solution
* Please review the full disclaimer at the bottom of this page.